Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.30 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.30 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
| ▸ | CD44 | P16070 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL525358 | 0.77 | — | — | |
| SCHEMBL2499867 | 0.67 | — | — | |
| SCHEMBL20511816 | 0.67 | PARP1 (0.46) | MAOBTSHRKDM1ACYP11B1CYP11B2 | |
| SCHEMBL20511815 | 0.67 | PARP1 (0.46) | MAOBTSHRKDM1ACYP11B1CYP11B2 | |
| SCHEMBL40790 | 0.67 | TSHR (0.45) | MAOBTSHRKDM1ACYP11B1CYP11B2 | |
| SCHEMBL2502153 | 0.63 | MAOA (0.32) | MAOBTSHRPARP1 | |
| SCHEMBL2680 | 0.63 | — | — | |
| SCHEMBL11328700 | 0.62 | TSHR (0.60) | MAOBTSHRKDM1AHTR2CBCHE | |
| SCHEMBL29263188 | 0.62 | MAOB (0.40) | MAOBTSHRKDM1ACYP11B1CYP11B2 | |
| SCHEMBL9720203 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023240024-A1 | SULFAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | claimed |
| CN-112805381-A | Compositions and methods for treating and preventing neurological disorders | 优曼尼蒂治疗公司 | 2021-05-14 | — | — | CN | claimed |
| EP-3810777-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS | Yumanity Therapeutics, Inc. (US) | 2021-04-28 | — | — | EP | claimed |
| US-20110245156-A1 | NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | CYTOKINE PHARMASCIENCES, INC. (US) | 2011-10-06 | — | — | US | claimed |
| WO-2011073269-A1 | PIPERIDINE ARYL SULFONAMIDE DERIVATIVES AS KV1.3 MODULATORS | EVOTEC AG (DE) | 2011-06-23 | — | — | WO | claimed |
| WO-2011073276-A1 | BENZOXAZINE ARYL SULFONAMIDE DERIVATIVES AS KV1.3 MODULATORS | EVOTEC AG (DE) | 2011-06-23 | — | — | WO | claimed |
| WO-2010077740-A2 | NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | CYTOKINE PHARMASCIENCES, INC. (US) | 2010-07-08 | — | — | WO | claimed |
| EP-1134213-B1 | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides | PFIZER (US) | 2005-11-02 | — | — | EP | claimed |
| JP-2003526654-A | — | — | 2003-09-09 | — | — | JP | claimed |
| US-6555569-B2 | Especially for treatment of Chlamydia pneumoniae | PFIZER INC. | 2003-04-29 | — | — | US | claimed |
| EP-1136071-A2 | Use of glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-09-26 | — | — | EP | claimed |
| WO-2001068055-A1 | PHARMACEUTICAL COMPOSITIONS OF GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2001-09-20 | — | — | WO | claimed |
| EP-1134213-A2 | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides | PFIZER INC. (US) | 2001-09-19 | — | — | EP | claimed |
| US-6277877-B1 | GLYCOGEN PHOSPHORYLASE INHIBITOR; ANTIDIABETIC AGENTS | PFIZER, INC. | 2001-08-21 | — | — | US | claimed |
| US-6107329-A | HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS | PFIZER, INC. (US) | 2000-08-22 | — | — | US | claimed |
| EP-0978279-A1 | Inhibitors of human glycogen phosphorylase | Pfizer Products Inc. (US) | 2000-02-09 | — | — | EP | claimed |
| US-5952322-A | AMIDE-SUBSTITUTED BENZIMIDAZOLE, INDOLE DERIVATIVES | PFIZER INC. (US) | 1999-09-14 | — | — | US | claimed |
| EP-0846464-A2 | Use of glycogen phosphorylase inhibitor for reducing non-cardiac tissue damage resulting from ischemia | PFIZER INC. (US) | 1998-06-10 | — | — | EP | claimed |
| EP-0832065-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1996039384-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER, INC. (US) | 1996-12-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245156-A1 | NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | DDX5, SAMHD1, EIF2AK2 | MAOB 812/4885TSHR 4854/4885KDM1A 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.